You just read:

HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease

News provided by

HemaQuest Pharmaceuticals, Inc.

Apr 25, 2011, 05:00 ET